Research programme: phosphodiesterase inhibitors - Acorda Therapeutics

Drug Profile

Research programme: phosphodiesterase inhibitors - Acorda Therapeutics

Alternative Names: BTT 5001; ELB 526; ELB-WE-007; WE-1

Latest Information Update: 02 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator elbion NV
  • Developer Biotie Therapies Corp.
  • Class 3-ring heterocyclic compounds; Imidazoles; Pyrazines; Pyrimidines; Quinoxalines; Small molecules; Triazines
  • Mechanism of Action Phosphodiesterase 10A inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Inflammation; Schizophrenia

Most Recent Events

  • 04 Nov 2010 Biotie decides to exclusively focus on clinical development and announces a restructuring plan to spin-off its preclinical CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform to BioCrea
  • 04 Nov 2010 Discontinued - Preclinical for CNS disorders in Germany (PO)
  • 04 Nov 2010 Discontinued - Preclinical for Schizophrenia in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top